Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.
Compounders cast adrift after semaglutide shortage ends
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales of compounded semaglutide hard and lambasting the pharma industry for restricting access to GLP-1 drugs – bought a peptide facility to raise its manufacturing capacity, sparking a sharp drop in its share price.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...
24/7 Wall St. on MSN1d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback